1. Stein IF, Leventhal ML1935 Amenorrhea associated with polycystic ovaries. Am J Obstet Gynecol 29:181-191
2. Zawadski JK, Dunaif A1992 Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR eds. Polycystic Ovary Syndrome. Boston: Blackwell Scientific; 377-384
3. Adams J, Polson DW, Franks S1986 Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. British Medical Journal 293:355-359
4. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19-25
5. Revised 2003 consensus on diagnostic criteria and long-term health risks related to Polycystic Ovary Syndrome (PCOS). Hum Reprod 19:41-47
6. Balen AH, Laven JS, Tan SL, Dewailly D2003 Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 9:505-514
7. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF2006 Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 91:4237-4245
8. Polson DW, Adams J, Wadsworth J, Franks S1988 Polycystic ovaries--a common finding in normal women. Lancet 1:870-872
9. Clayton RN, Ogden V, Hodgkinson J, Worswick L, Rodin DA, Dyer S1992 How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? [see comments]. Clin Endocrinol 37:127-134
10. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89:2745-2749
11. Coney P, Ladson G, Sweet S, Legro RS2008 Does polycystic ovary syndrome increase the disparity in metabolic syndrome and cardiovascular-related health for African-American women? Semin Reprod Med 26:35-38
12. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC2006 PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. Bjog 113:1210-1217
13. Ehrmann DA2005 Polycystic ovary syndrome. N Engl J Med 352:1223-1236
14. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C1995 Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 10:2107-2111
15. Legro RS, Myers ER, Barnhart HX, Carson SA, Diamond MP, Carr BR, Schlaff WD, Coutifaris C, McGovern PG, Cataldo NA, Steinkampf MP, Nestler JE, Gosman G, Guidice LC, Leppert PC2006 The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril 86:914-933
16. Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, Wood JR, Legro RS, Strauss JFr, McAllister JM2004 Feb Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 145:799-808
17. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV1993 Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329:1383-1388
18. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F1976 Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 57:1320-1329
19. Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA1989 Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med 320:559-565
20. Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld DH1997 Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2248-2256
21. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SSC1996 Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome - common and distinct features. J Clin Endocrinol Metab 81:2854-2864
22. Schneyer AL, Fujiwara T, Fox J, Welt CK, Adams J, Messerlian GM, Taylor AE2000 Dynamic changes in the intrafollicular inhibin/activin/follistatin axis during human follicular development: relationship to circulating hormone concentrations. J Clin Endocrinol Metab 85:3319-3330
23. Nelson VL, Legro RS, Strauss JF, III, McAllister JM1999 Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Molecular Endocrinology 13:946-957
24. Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R2001 Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 75:53-58
25. Sam S, Legro RS, Essah PA, Apridonidze T, Dunaif A2006 Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A 103:7030-7035
26. Legro RS, Driscoll D, Strauss JF, 3rd, Fox J, Dunaif A1998 Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 95:14956-14960
27. Kumar A, Woods KS, Bartolucci AA, Azziz R2005 Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 62:644-649
28. Legro RS, Kunselman AR, Demers L, Wang SC, Bentley-Lewis R, Dunaif A2002 Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab 87:2134-2138
29. Stewart DR, Dombroski B, Urbanek M, Ankener W, Ewens KG, Wood JR, Legro RS, Strauss JF, 3rd, Dunaif A, Spielman RS2006 Fine Mapping of Genetic Susceptibility to Polycystic Ovary Syndrome on Chromosome 19p13.2 and Tests for Regulatory Activity. J Clin Endocrinol Metab
30. Webber LJ, Stubbs S, Stark J, Trew GH, Margara R, Hardy K, Franks S2003 Sep 27 Formation and early development of follicles in the polycystic ovary. Lancet 362:1017-1021
31. Webber LJ, Stubbs SA, Stark J, Margara RA, Trew GH, Lavery SA, Hardy K, Franks S2007 Prolonged survival in culture of preantral follicles from polycystic ovaries. J Clin Endocrinol Metab 92:1975-1978
32. Dunaif A, Segal KR, Futterweit W, Dobrjansky A1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38:1165-1174
33. Dunaif A, Finegood DT1996 Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:942-947
34. Chang RJ, Nakamura RM, Judd HL, Kaplan SA1983 Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 57:356-359
35. O'Meara NM, Blackman JD, Ehrmann DA, Barnes RB, Jaspan JB, Rosenfield RL, Polonsky KS1993 Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 76:1241-1247
36. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Polonsky KS1997 Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82:2108-2116
37. Adashi EY, Hsueh AJ, Yen SS1981 Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 108:1441-1449
38. Nandi A, Kitamura Y, Kahn CR, Accili D2004 Mouse models of insulin resistance. Physiol Rev 84:623-647
39. Dunaif A1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. . Endocr Rev 18:774-800
40. Barbieri RL, Ryan KJ1983 Sep 1 Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. [Review] [70 refs] American Journal of Obstetrics & Gynecology 147:90-101
41. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN2006 Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91:48-53
42. Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ1994 Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 79:265-271
43. Willis D, Franks S1995 Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab 80:3788-3790
44. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, RittmasterRS., Clore JN, Blackard WG1991 A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72:83-89
45. Nestler JE2008 Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 358:47-54
46. Goldzieher JW, Axelrod LR1963 Clinical and biochemical features of polycystic ovarian disease. Fertil Steril 14:631-653
47. Teilmann G, Pedersen CB, Jensen TK, Skakkebaek NE, Juul A2005 Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics 116:1323-1328
48. Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J2000 Jan Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. . Human Reproduction 15:24-28
49. Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP2000 Apr Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. . Fertility & Sterility 73:724-729
50. Elting MW, Kwee J, Korsen TJ, Rekers-Mombarg LT, Schoemaker J2003 May Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil Steril 79:1154-1160
51. Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC2006 A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update 12:13-21
52. Roland M1970 Problems of ovulation induction with clomiphene citrate with report of a case of ovarian hyperstimulation. Obstet Gynecol 35:55-62
53. Thiboutot D, Jabara S, McAllister JM, Sivarajah A, Gilliland K, Cong Z, Clawson G2003 Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol 120:905-914
54. Legro RS, Carmina E, Stanczyk FZ, Gentzschein E, Lobo RA1994 Alterations in androgen conjugate levels in women and men with alopecia. Fertil Steril 62:744-750
55. Hardiman P, Pillay OS, Atiomo W2003 May 24 Polycystic ovary syndrome and endometrial carcinoma. Lancet 361:1810-1812
56. Dahlgren E, Friberg LG, Johansson S, Lindstrom B, Oden A, Samsioe G1991 Endometrial carcinoma; ovarian dysfunction--a risk factor in young women. European Journal of Obstetrics,Gynecology,& Reproductive Biology 41:143-150
57. Dahlgren E, Johansson S, Oden A, Lindstrom B, Janson PO1989 A model for prediction of endometrial cancer. Acta Obstetricia et Gynecologica Scandinavica 68:507-510
58. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP2001 Feb Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. . Journal of Clinical Endocrinology & Metabolism 86:517-520
59. Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP2001 Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 86:1175-1180
60. Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, Pories W, Courcoulas A, McCloskey C, Mitchell J, Patterson E, Pomp A, Staten MA, Yanovski SZ, Thirlby R, Wolfe B2009 Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 361:445-454
61. Ehrmann DA, Kasza K, Azziz R, Legro RS, Ghazzi MN2005 Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:66-71
62. Legro RS, Kunselman AR, Dodson WC, Dunaif A1999 Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. . Journal of Clinical Endocrinology & Metabolism 84:165-169
63. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Morselli-Labate AM, Pagotto U, Pasquali R2004 Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 53:2353-2358
64. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A2005 Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 90:3236-3242
65. Legro RS2003 Polycystic ovary syndrome and cardioivascular disease: A premature association? Endocrine Reviews In Press
66. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE2002 May Menstrual cycle irregularity and risk for future cardiovascular disease. Journal of Clinical Endocrinology & Metabolism 87:2013-2017
67. Krentz AJ, von Muhlen D, Barrett-Connor E2007 Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause 14:284-292
68. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ2008 Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 93:1276-1284
69. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH2000 Nov Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. . Arteriosclerosis, Thrombosis & Vascular Biology 20:2414-2421
70. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS2004 Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:5454-5461
71. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PFn, Fitzpatrick LA2003 Jun Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism 88:2562-2568
72. Reaven GM1988 Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607
73. Legro RS, Kunselman AR, Dunaif A2001 Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111:607-613
74. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA1998 Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. . Journal of Clinical Epidemiology 51:415-422
75. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A1992 Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstetricia et Gynecologica Scandinavica 71:599-604
76. Holte J, Gennarelli G, Berne C, Bergh T, Lithell H1996 Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod 11:23-28
77. Barnard L, Ferriday D, Guenther N, Strauss B, Balen AH, Dye L2007 Quality of life and psychological well being in polycystic ovary syndrome. Hum Reprod 22:2279-2286
78. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A2007 Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril 87:1369-1376
79. Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, Cook D, Dunaif A1998 Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 83:1976-1987
80. Jones GL, Hall JM, Balen AH, Ledger WL2008 Health-related quality of life measurement in women with polycystic ovary syndrome: a systematic review. Hum Reprod Update 14:15-25
81. Robinson S, Rodin DA, Deacon A, Wheeler MJ, Clayton RN1992 Which hormone tests for the diagnosis of polycystic ovary syndrome? [see comments]. British Journal of Obstetrics & Gynaecology 99:232-238
82. New MI, Speiser PW1986 Genetics of adrenal steroid 21-hydroxylase deficiency. [Review] [115 refs]. Endocr Rev 7:331-349
83. Azziz R, Hincapie LA, Knochenhauer ES, Dewailly D, Fox L, Boots LR1999 Nov Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. . Fertility & Sterility 72:915-925
84. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM2008 The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526-1540
85. Waggoner W, Boots LR, Azziz R1999 Dec Total testosterone and dheas levels as predictors of androgen-secreting neoplasms: a populational study. . Gynecological Endocrinology 13:394-400
86. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H2007 Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 92:405-413
87. Cheung AP2001 Ultrasound and menstrual history in predicting endometrial hyperplasia in polycystic ovary syndrome. Obstet Gynecol 98:325-331
88. McGovern PG, Legro RS, Myers ER, Barnhart HX, Carson SA, Diamond MP, Carr BR, Schlaff WD, Coutifaris C, Steinkampf MP, Nestler JE, Gosman G, Leppert PC, Giudice LC2007 Utility of screening for other causes of infertility in women with "known" polycystic ovary syndrome. Fertil Steril 87:442-444
89. 2008 Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 23:462-477
90. 2008 Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 89:505-522
91. Asch RH, Greenblatt RB1976 Sep Update on the safety and efficacy of clomiphene citrate as a therapeutic agent. [Review] [59 refs] Journal of Reproductive Medicine 17:175-180
92. Gysler M, March CM, Mishell DR, Jr., Bailey EJ1982 A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril 37:161-167.
93. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER2007 Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356:551-566
94. Rausch ME, Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER, Coutifaris C2009 Predictors of Pregnancy in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab
95. Lobo RA, Granger LR, Davajan V, Mishell DR, Jr.1982 An extended regimen of clomiphene citrate in women unresponsive to standard therapy. Fertil Steril 37:762-766
96. Branigan EF, Estes MA2003 A randomized clinical trial of treatment of clomiphene citrate-resistant anovulation with the use of oral contraceptive pill suppression and repeat clomiphene citrate treatment. Am J Obstet Gynecol 188:1424-1428; discussion 1429-1430
97. Lobo RA, Paul W, March CM, Granger L, Kletzky OA1982 Clomiphene and dexamethasone in women unresponsive to clomiphene alone. Obstet Gynecol 60:497-501
98. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R1998 Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338:1876-1880
99. Elnashar A, Abdelmageed E, Fayed M, Sharaf M2006 Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod 21:1805-1808
100. Beck J, Boothroyd C, Proctor M, Farquhar C, Hughes E2005 Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation. Cochrane Database Syst Rev:CD002249
101. Christin-Maitre S, Hugues JN2003 A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod 18:1626-1631
102. Farquhar C, Lilford RJ, Marjoribanks J, Vandekerckhove P2007 Laparoscopic 'drilling' by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev:CD001122
103. Bayram N, van Wely M, Kaaijk EM, Bossuyt PM, van der Veen F2004 Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. Bmj 328:192
104. Lemieux S, Lewis GF, Ben-Chetrit A, Steiner G, Greenblatt EM1999 Nov Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels. . Journal of Clinical Endocrinology & Metabolism 84:4278-4282
105. Donesky BW, Adashi EY1996 Surgical ovulation induction: the role of ovarian diathermy in polycystic ovary syndrome. [Review]. Baillieres Clinical Endocrinology & Metabolism 10:293-309
106. Casper RF, Mitwally MF2006 Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 91:760-771
107. Creanga AA, Bradley HM, McCormick C, Witkop CT2008 Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol 111:959-968
108. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F2006 Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. Bmj 332:1485
109. Nestler JE, Jakubowicz DJ1996 Decreases in ovarian cytochrome P450C17-alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335:617-623
110. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research G2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 346:393-403
111. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M2000 Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85:139-146
112. Lord JM, Flight IH, Norman RJ2003 Oct 25 Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327:951-953
113. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS2004 A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 82:421-429
114. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS2008 The Impact of Metformin, Oral Contraceptives and Lifestyle Modification, on Polycystic Ovary Syndrome in Obese Adolescent Women in Two Randomized, Placebo-Controlled Clinical Trials. J Clin Endocrinol Metab
115. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH2006 Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 21:80-89
116. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW2003 Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 79:562-566
117. Rouzi AA, Ardawi MS2006 A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril 85:428-435
118. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R1996 The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:3299-3306
119. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN, PCOS/Troglitazone Study G2001 Apr Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. . Journal of Clinical Endocrinology & Metabolism 86:1626-1632
120. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE2004 Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 82:893-902
121. Penna IA, Canella PR, Reis RM, Silva de Sa MF, Ferriani RA2005 Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Hum Reprod 20:2396-2401
122. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R2008 Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 93:2670-2678
123. Vessey MP, Painter R1995 Jun Endometrial and ovarian cancer and oral contraceptives--findings in a large cohort study. . British Journal of Cancer 71:1340-1342
124. Schlesselman JJ1997 Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum Reprod 12:1851-1863
125. Chasen-Taber L, Willett WC, Stampfer MJ, Hunter DJ, Colditz GA, Spielgelman D, Manson JE1997 A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 20:330-335
126. Meyer C, McGrath BP, Teede HJ2007 Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30:471-478
127. Korytkowski MT, Mokan M, Horwitz MJ, Berga SL1995 Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J Clin Endocrinol Metab 80:3327-3334
128. Falsetti L, Pasinetti E1995 Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Acta Obstetricia et Gynecologica Scandinavica 74:56-60
129. Costello MF, Shrestha B, Eden J, Johnson NP, Sjoblom P2007 Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum Reprod
130. Legro RS, Pauli JG, Kunselman AR, Meadows JW, Kesner JS, Zaino RJ, Demers LM, Gnatuk CL, Dodson WC2008 Effects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab 93:420-429
131. Anttila L, Koskinen P, Erkkola R, Irjala K, Ruutiainen K1994 Serum testosterone, androstenedione and luteinizing hormone levels after short-term medroxyprogesterone acetate treatment in women with polycystic ovarian disease. Acta Obstetricia et Gynecologica Scandinavica 73:634-636
132. Kriplani A, Singh BM, Lal S, Agarwal N2007 Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia. Int J Gynaecol Obstet
133. Xiao B, Wu SC, Chong J, Zeng T, Han LH, Luukkainen T2003 Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril 79:963-969
134. Tamaoka Y, Orikasa H, Sumi Y, Sakakura K, Kamei K, Nagatani M, Ezawa S2004 Treatment of endometrial hyperplasia with a danazol-releasing intrauterine device: a prospective study. Gynecol Obstet Invest 58:42-48
135. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ2007 Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 92:456-461
136. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL2009 The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. J Clin Endocrinol Metab 94:103-108
137. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H2004 Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683-2693
138. Moran LJ, Brinkworth G, Noakes M, Norman RJ2006 Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online 12:569-578
139. Moran LJ, Noakes M, Clifton PM, Wittert GA, Williams G, Norman RJ2006 Short-term meal replacements followed by dietary macronutrient restriction enhance weight loss in polycystic ovary syndrome. Am J Clin Nutr 84:77-87
140. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, de Jonge L, Greenway FL, Loria CM, Obarzanek E, Williamson DA2009 Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 360:859-873
141. Vigorito C, Giallauria F, Palomba S, Cascella T, Manguso F, Lucci R, De Lorenzo A, Tafuri D, Lombardi G, Colao A, Orio F2007 Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 92:1379-1384
142. Robinson MK2009 Surgical treatment of obesity--weighing the facts. N Engl J Med 361:520-521
143. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millan JL2005 The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 90:6364-6369
144. Eid GM, Cottam DR, Velcu LM, Mattar SG, Korytkowski MT, Gosman G, Hindi P, Schauer PR2005 Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg Obes Relat Dis 1:77-80
145. Marceau P, Kaufman D, Biron S, Hould FS, Lebel S, Marceau S, Kral JG2004 Outcome of pregnancies after biliopancreatic diversion. Obes Surg 14:318-324
146. Sheiner E, Levy A, Silverberg D, Menes TS, Levy I, Katz M, Mazor M2004 Pregnancy after bariatric surgery is not associated with adverse perinatal outcome. Am J Obstet Gynecol 190:1335-1340
147. Weiss HG, Nehoda H, Labeck B, Hourmont K, Marth C, Aigner F2001 Pregnancies after adjustable gastric banding. Obes Surg 11:303-306
148. Lindholm A, Bixo M, Bjorn I, Wolner-Hanssen P, Eliasson M, Larsson A, Johnson O, Poromaa IS2008 Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil Steril 89:1221-1228
149. Sabuncu T, Harma M, Nazligul Y, Kilic F2003 Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil Steril 80:1199-1204
150. Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G2008 Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril 89:899-906
151. Diamanti-Kandarakis E, Piperi C, Alexandraki K, Katsilambros N, Kouroupi E, Papailiou J, Lazaridis S, Koulouri E, Kandarakis HA, Douzinas EE, Creatsas G, Kalofoutis A2006 Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metabolism 55:494-500
152. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL2005 Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab 90:729-733
153. Swiglo BA, Cosma M, Flynn DN, Kurtz DM, Labella ML, Mullan RJ, Erwin PJ, Montori VM2008 Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J Clin Endocrinol Metab 93:1153-1160
154. Helfer EL, Miller JL, Rose LI1988 Jan Side-effects of spironolactone therapy in the hirsute woman. . Journal of Clinical Endocrinology & Metabolism 66:208-211
155. Palep-Singh M, Mook K, Barth J, Balen A2004 An observational study of Yasmin in the management of women with polycystic ovary syndrome. J Fam Plann Reprod Health Care 30:163-165
156. Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, Pagotto U, Pasquali R2006 Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 91:3970-3980
157. Wolf JES, D. Huber, F., Jackson, J. Lin, C.S., Mathes, B.M., Schrode, K. and the Eflornithine HCl Study Group2007 Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCL 13.9% cream in the treatment of women with facial hair. Int J Derm 207:94-98
158. Palomba S, Orio F, Jr., Falbo A, Manguso F, Russo T, Cascella T, Tolino A, Carmina E, Colao A, Zullo F2005 Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:4068-4074
159. Zain MM, Jamaluddin R, Ibrahim A, Norman RJ2009 Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 91:514-521
160. Bayar U, Tanriverdi HA, Barut A, Ayoglu F, Ozcan O, Kaya E2006 Letrozole vs. clomiphene citrate in patients with ovulatory infertility. Fertil Steril 85:1045-1048
161. Atay V, Cam C, Muhcu M, Cam M, Karateke A2006 Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Int Med Res 34:73-76
162. Badawy A, Abdel Aal I, Abulatta M2007 Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial. Fertil Steril
163. Begum MR, Ferdous J, Begum A, Quadir E2008 Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. Fertil Steril